From evaluation to treatment

Rehabilitation in progressive ­multiple sclerosis

Publication Date: 19.09.2018
Swiss Arch Neurol Psychiatr Psychother. 2018;169(06):183-184

Michael Hauptsa,b, Dietmar Seidela

a Augustahospital Anholt, Isselburg-Anholt, Germany

b Department of Neurology, University Hospital Dusseldorf, Germany

Probably half of the multiple sclerosis (MS) patients worldwide have progressive MS (PMS) and seek therapy beyond prevention of inflammatory bouts. Therapy plans in PMS have to focus on improvement of abilities in individual problem constellations. Standardized assessment methods in MS beyond the expanded disability status scale (EDSS) have been ­developed.

Recent studies show positive effects for activating therapies in immobile MS patients. Fair evidence exists for several nonpharmacological therapies. Some data indicate activation of neurotrophic factors and neuroplasticity during therapy. Few medication strategies including corticoid pulses are at hand for PMS. Combined pharmacological and multimodal symptomatic approaches promise increased efficacy. Complex inpatient therapy schemes may be of special value for severely affected patients.

Key words: progressive multiple sclerosis (PMS) assessment methods expanded disability status scale (EDSS) therapy concepts combined multimodal non-pharmacological therapies neuroplasticity


Progressive multiple sclerosis (PMS) affects probably half of multiple sclerosis patients worldwide. Both ­secondary PMS and primary PMS typically start after the age of 40 years [1], and are subsumed under PMS in recent ­criteria (either “active” or “non-active”) [2].

The pathological bases of axonal loss and tissue ­atrophy may include diffuse or focal inflammation in meninges and parenchyma, mitochondrial defi­ciencies, oligodendrocyte dysfunction and micro­vascular changes [3]. Most in-vivo research is based on brain ­imaging data: magnetic resonance imaging (MRI) demonstrates brain atrophy. Spinal cord and gray matter atrophy are typical features of PMS. ­Optical coherence tomography shows retinal layer ­atrophy, which correlates with neurodegeneration [4].


Several methods for the clinical assessment of PMS have evolved. With different neurological disabilities occurring with chronic disease, patient perspectives and quality of life are important assessment ­objectives [5]. From a patient perspective, a number of important disabling conditions characterise PMS: ­mobility/gait problems (ataxia, spasticity), bladder dysfunction, ­fatigue, failing cognition, depression. All these bring increased rates of unemployment, social handicaps and increasing costs for society, persons with MS and their caregivers [6].

In a majority of cases PMS shows a spinal pattern of ­impairment – para- or tetraparesis, neurogenic bladder and impairment of gait. This pattern is reflected in the expanded disability status scale (EDSS [7]), with gait impairment as the main criterion from grade 4 ­onward; grade 6 equals loss of unaided walking. As the EDSS does not fully represent all important functional deficits, and has non-continueous steps, other standardised instruments are used. The EDSS scores walking “at all”, whereas assessing “walking ­distance in a given time” or “time needed for a given distance” (see table 1; [8]) yields more precise results.

An important additional burden with PMS stems from ­comorbidities, increasing the need for help and hospitalisations [9], and also aggravating MS disability. They deserve notice; urosepsis, aspiration pneumonia or ­infected ulcers may be lethal.

Table 1: Examples of PMS assessments.
Assessment domainTests
Neurological systems, mobility: 
Expanded disability status scaleEDSS
a) 2-minute-walking test, 6-minute 
walking test 
b) preset distance timed walk: 25 ft. timed walking test; timed-up-and-goa) 2MWT, 6 MWT.
b) 25FTWT; TUG
Hand function: 9-hole peg test9-HPT
Bladder: infection; residual volume after voiding?Urinalysis; sonography
Fatigue: fatigue scales (self-reported questionaires, quantitative score ­results)FSS; MFIS; MSFC; ­Weimus
Cognition: a) neuropsychological ­batteries; b) screening testsa) MACFIMS; BRB; ­BICAMS b) SDMT, ­PASAT; MUSIC
a) psychiatric criteria 
(such as ICD, DSM); 
b) self-reported questionaires 
(quantitative scores)b) Beck Depression Inventory (BDI version II), Hamilton Anxiety and Depression Scale (HADS)
Personal functioning (everyday life, job, social etc.)ICF assessment

Therapy rationale

Improvement of abilities is a key objective in PMS ­therapy. Thus it has to be symptom oriented and faces individual problem constellations. Few symptomatic therapies in PMS are evidence based, therefore. Unfortunately, most studies are small, often ­underpowered for statistics, and mix relapsing-remitting multiple sclerosis (RRMS) and primary or secondary PMS [10, 11]. Besides neurogenic pathology, secondary maladaptive functional patterns, psychosocial factors and loss of physical fitness (“deconditioning”) deserve attention. Several studies showed positive effects of ­activating therapies in immobile MS patients. Fair ­evidence exists for a number of nonpharmacological therapies [5, 10, 11], which are summarised in the table 2. A multi­disciplinary team approach is preferable in PMS.

PMS patients may be too handicapped for many single therapies. For these situations, inpatient treatment is advisable. After complex inpatient therapy, positive results with enduring effects have been demonstrated repeatedly [5, 10, 20, 21].

Table 2: Symptomatic therapies in PMS.
Physical exercise, 
endurance/resistance trainingAntispasticity muscle-­relaxants
Physiotherapy Anticholinergic bladder drugs
Occupational therapyAntiepileptic channel ­blockers (neuropathic pain)
Speech/swallowing therapyAntidepressive drugs
Behavioural therapy, psychologyCorticoid pulses
Educational programsBotulinum toxin
Multimodal rehabilitationTHC/CBD (cannabinoid spray)


Few types of medication are available for PMS (see ­table 2) and side effects may be relevant. The benefits of disease-modifying drugs are limited as yet. Repe­titive corticoid pulses may be beneficial in PMS, in terms of reduction of silent ­inflammation and of ­spasticity, for some time [12]. In PMS, pulses might be administered ­intramuscularly, orally or intrathecally, as well as via intravenous infusion. Simultaneous combination with multimodal therapies is more effective [13].

Diaminopyridine (improving gait for about 25% of ­patients [14]), cannabinoid spray (THC/CBD) for spas­ticity (effective in about 50% [15]), and botulinum toxin for circumscribed muscle groups and the bladder were introduced more recently. Treating spasticity may also reduce pain. Drugs such as biotin promise ­axonal energy and structure restoration in PMS but still lack confirmation [16].

Lasting therapy effects

In a spasticity study with THC/CBD [15], ­antispastic ­effects were seen for several months after active ­treatment. Explanations for such prolonged functional improvements may be retraining, deblockade of phy­siological functioning, and even neuroplasticity [17]. Some data indicate activation of neurotrophic factors through physical exercise in MS [18, 19].

Other important issues of PMS therapy include information, counseling and education of patients and ­caregivers. Reduction of uncertainty, fear and depression may help improve quality of life and personal functioning [5]. A team approach combining medication strategies, multimodal symptomatic therapies, expert nursing and experienced neurologists in a time-synchronised effort seems most promising.

Key points

• Standardised assessment methods valuable

• Growing evidence for benefits of physical exercise

• Multidisciplinary therapy team approach superior to single measures

• Combined pharmocology + multimodal symptomatic ­approaches more effective

• Perspective for neuroplasticity, neurotrophic factor´ ­activation, functional reorganisation through therapy ­procedures

Funding / potential competing interests

No financial support and no other potential conflict of interest ­relevant to this article was reported.


Michael Haupts, MD
Augustahospital Anholt
Augustastr. 8
DE-46419 Isselburg-Anholt


 1 Confavreux C, Vukusic S. Natural history of multiple sclerosis. Brain. 2006;129(Pt 3):606–16.

 2 Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sorensen PS, ­Thompson AJ, et al. Defining the clinical course of multiple ­sclerosis: The 2013 revisions. Neurology. 2014;83(3):278–86.

 3 Lassmann H, van Horssen J, Mahad D. Progressive multiple ­sclerosis: pathology and pathogenesis. Nat Rev Neurol. 2012;8(11):647–56.

 4 Saidha S, Al-Louzi O, Ratchford JN Bhargava P, Oh J, Newsome SD, et al. Optical coherence tomography reflects brain atrophy in ­multiple sclerosis: a four-year study. Ann Neurol. 2015;78(5):801–13.

 5 Beer S, Khan F, Kesselring J. Rehabilitation interventions in ­multiple sclerosis: an overview. J Neurol. 2012;259(9):1994–2008.

 6 Kobelt G, Berg J, Lindgren P, Elias WG, Flachenecker P, Freidel M, et al. Costs and quality of life of multiple sclerosis in Germany. Eur J Health Econ. 2006;7(Suppl 2):S34–44.

 7 Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;30:­299–302.

 8 Plantone D, De Angelis F, Doshi A, Chataway J. Secondary Multiple Sclerosis: Definition and Measurement. CNS Drugs. 2016;30:517–26.

 9 Marrie RA, Elliot L, Marriott J, Cossoy M, Tennakoon A, Yu N, et al. Comorbidity increases the risk of hospitalizations in multiple ­sclerosis. Neurology. 2015;84(4):350–58.

10 Feinstein A, Freeman J, Lo A. Treatment of progressive multiple ­sclerosis: Lancet Neurol. 2015;14:194–207.

11 Khan F, Amatya B: Rehabilitation in Multiple Sclerosis: a syste­matic review of systematic reviews. Arch Phys Med Rehab. 2017;98:353–67.

12 Milligan NM, Newcombe R, Compston DAS. A double-blind ­controlled trial of high-dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. JNNP. 1987;50:511–16.

13 Craig J, Young CA, Ennis M, Baker G, Boggild M. A randomised ­controlled trial comparing rehabilitation against standard therapy in multiple sclerosis patients receiving intravenous steroid treatment. J Neurol Neurosurg Psychiatry. 2003;74(9):1225–30.

14 Goodman AD, Brown TE, Krupp LB, Schapiro RT, Schwid SR, ­Cohen R, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009; 373(9665):732–8.

15 Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, ­Zapletalova O, et al. A randomized, double-blind, placebo-­controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur Neurol. 2011;18:1122–31.

16 Tourbah A, Lebrun-Frenay C, Edan G, Clanet M, Papeix C, ­Vukusic S, et al. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-­controlled study. Mult Scler. 2016;22(13):1719–22.

17 Tomassini V, Matthews PM, Thompson AJ, Fuglo D, Geurts JJ, ­Johansen-Berg H, et al. Neuroplasticity and functional recovery in multiple sclerosis. Nat Rev Neurol. 2012;8(11):635–46.

18 Bansi J, Bloch W, Gamper U, Kesselring J. Training in MS: influence of two different endurance training protocol (aquatic versus overland) on cytokine and neurotrophin concentrations during three week randomized controlled trial. Mult Scler. 2013;19(5):613–21.

19 Briken S, Rosenkranz SC, Keminer O, Patra S, Ketels G, Heesen C, et al. Effects of exercise on Irisin, BDNF and IL-6 serum levels in patients with progressive multiple sclerosis. J Neuroimmunol. 2016;299:53–8.

20 Freeman JA, Langdon DW, Hobart JC, Thompson AJ. The impact of inpatient rehabilitation on progressive multiple sclerosis. Ann Neurol. 1997;42:236–44.

21 Solari A, Fillipini G, Gasco P, Colla L, Salmaggi A, La Mantia L, et al. Physical therapy has a positive effect on disability in multiple ­sclerosis patients. Neurology. 1999;52(1):57–62.

Verpassen Sie keinen Artikel!